CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
CHAMPIONS ONCOLOGY, INC.
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026
$4.69−0.01 (-0.21%)
Close on Oct 19, 2026
- Market cap
- $65.18M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2026
Gross margin
48.0%+0.3 pts over 5 years
Operating margin
-1.9%−2.8 pts over 5 years
Net margin
-2.0%−2.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +4.4% | +3.3% | +7.7% | +18.2% | |
| Gross profit | -0.1% | +5.4% | +7.8% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | -2158.0% | 5.8% | -30.5% | |
| Return on assets | -99.9% | 1.5% | -4.0% | |
| Current ratio | 0.79 | 1.13 | 0.96 | |
| Capex to revenue | 5.0% | 8.0% | 0.9% | |
| Diluted shares | 11M | 15M | 14M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Champions Oncology generated $28.46M from operations and spent $7.75M on capital expenditure, dividends and share buybacks. 91% of that went back into the business.
Generated
$28.46M
Used
$7.75M
Capital expenditure$7.05M91%Dividends$00%Share buybacks$708.00K9%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-2.0%
×Asset turnover2.00×
×Equity multiplier7.69×
=Return on equity, FY2026-30.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | -2.0% | 2.00× | 7.69× | -30.5% |
| FY2025 | 8.3% | 1.95× | 31.29× | 503.0% |
| FY2024 | -14.5% | 1.66× | 22.12× | -532.5% |
| FY2023 | -9.9% | 1.55× | 5.07× | -77.7% |
| FY2022 | 1.1% | 1.56× | 3.81× | 6.6% |
| FY2021 | 0.9% | 1.70× | 3.86× | 5.8% |
| FY2020 | -6.5% | 2.01× | 4.42× | -57.8% |
| FY2019 | 4.4% | 0.30× | 9.04× | 12.0% |
| FY2018 | -7.3% | 2.52× | 39.92× | -732.5% |
| FY2017 | -44.7% | 2.24× | 21.61× | -2158.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
2of 8 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero-$1.18M
- Cash generatingOperating cash flow above zero-$4.47M
- Return on assets improvedROA up on the prior year18.0% → -3.6%
- Earnings backed by cashOperating cash flow above net income-$4.47M vs -$1.18M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.94 → 0.96
- No dilutionShare count did not rise14M → 14M
- Gross margin improvedGross margin up on the prior year50.15% → 48.00%
- More efficientAsset turnover rose2.18 → 1.84